Kim et al. (2022) claimed that the anti-carcinogenic effects of Nobiletin against triple-negative breast cancer when administered alone or in combination are due to its regulatory effect on the ROR-IκBα/NFκB pathway and that it has good potential for therapeutic strategy in cancer and inflammation. This evidence concerns the gene NFKBIA and triple-negative breast carcinoma.